Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment. Check your account now to learn when your revalidation is due. More information here.

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: June 2, 2010

Drug Name	Review Type	Class	Manufacturer
Victoza	New Drug Initial Review	GLP-1 Receptor Agonist	Novo Nordisk
Kalbitor	New Drug Initial Review	Orphan Biologic � for HAE	Dyax
Intuniv	New Drug Initial Review	ADHD Agents	Shire
Fanapt	New Drug Initial Review	Atypical Antipsychotic	Novartis
Effient	New Drug Initial Review	Platelet Aggregation Inhibitor	Eli Lilly
Ampyra	New Drug Initial Review	Multiple Sclerosis Agents	Acorda
Xifaxan 550	New Drug Initial Review	Antibiotic	Salix
Cayston	New Drug Initial Review	Antibiotic	Gilead
Renvela	New Drug Appeal	Phosphate Binder	Genzyme
Byetta	New Drug Appeal	GLP-1 Receptor Agonist	Amylin
Invega Sustenna	New Drug Appeal	Atypical Antipsychotic	Ortho McNeil Janssen
Multaq	New Drug Appeal	Antiarrhythmic	Sanofi
Twynsta	New Drug Appeal	Antihypertensive Combination	Boehringer Ingelheim
Zemplar	New Drug Appeal	Hyperparathyroidism due to CKD	Abbott
Toviaz	New Drug Appeal	Urinary Anti-Incontinence	Pfizer
Vivitrol	New Drug Appeal	Opioid Antagonist	Alkermes

Footer